AZN

Ozempic Linked To Lower Risk Of Violence In New Study

FDA Accepts AstraZeneca's Filing for Expanded Use of Ultomiris

AstraZeneca Stock Down 7% in 3 Months: Should You Buy, Sell or Hold?

TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer

Astrazeneca (AZN) Outperforms Broader Market: What You Need to Know

BioInvent's BI-1206 Triplet Achieves 83% Response Rate in Refractory NHL with Improved Safety vs. SOC (EHA 2026)

AstraZeneca's GLP-1 Pill Heads To Late-Stage Trials